Patient
-
Stock via Getty Images
10 of our most read articles of 2024
The high drama of an election year, industry layoffs, patent cliff strategies and other key trends that shaped pharma in 2024.
By Meagan Parrish • Dec. 20, 2024 -
PeopleImages via Getty Images
Maternal mortality trends remain dire — and researchers face an uphill battle to solve them
Rising maternal mortality, particularly among vulnerable populations, stems in part from a lack of research in pregnant women.
By Michael Gibney • Dec. 17, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
Courtesy of Roche
3 closely watched drugs that failed in the clinic
How recent setbacks and scattered successes could impact various sectors of the industry.
By Kelly Bilodeau • Dec. 16, 2024 -
Stock via Getty Images
Will the ‘anti-woke’ movement derail DEI efforts in pharma?
Amid the DEI backlash in corporate America, pharma leaders are quietly adjusting tactics.
By Meagan Parrish • Dec. 13, 2024 -
Pony Wang via Getty Images
Deep DiveEndometriosis drug research, long underfunded, confronts familiar problems in women’s health
Despite the disease’s prevalence, endometriosis remains misunderstood, and research into drugs that might treat it draws scant funding — problems that have deep roots.
By Delilah Alvarado • Dec. 11, 2024 -
Permission granted by Alexion/AstraZeneca
How Alexion markets a rare disease drug by ‘starting with the end in mind’
The biopharma, now an arm of AstraZeneca, needs to build the plane while flying it to be first in rare diseases with no other option.
By Michael Gibney • Dec. 3, 2024 -
Stock via Getty Images
Can the girl power of Arrivo’s depression drug help reverse its fortunes?
After failing a mid-stage trial, the biotech shifted course and is now targeting females with the goal of proving gender can play a role in depression outcomes.
By Kelly Bilodeau • Dec. 3, 2024 -
Getty Images via Getty Images
Specialized CROs aim to boost participation among women and other underrepresented groups
Lindus Health’s women-focused CRO is the latest in a handful of research efforts to target specialized — and underrepresented — populations.
By Alexandra Pecci • Nov. 27, 2024 -
Permission granted by Pfizer
Pfizer and Lilly’s telehealth prescribing platforms draw Senate scrutiny for ‘potential fraud’
As Big Pharma embraces telehealth to sell medicines directly to patients, lawmakers wonder whether the programs skirt anti-kickback rules.
By Kelly Bilodeau • Nov. 12, 2024 -
Permission granted by Sernova
ProfileCEO with type 1 diabetes works to deliver ‘world’s first’ functional cure
Sernova’s technology helped type 1 diabetes patients achieve insulin independence in early- and mid-stage trials.
By Alexandra Pecci • Nov. 5, 2024 -
123RF/ Jozef Polc
Sponsored by CareMetxNo more delays: Accelerating therapy starts by embedding hub services in provider workflows
Integrating patient access programs with the systems healthcare providers use daily increases speed to therapy.
By Shabbir Ahmed, Chief Commercial Officer at CareMetx • Nov. 4, 2024 -
Stock via Getty Images
A sickle cell cure exists. But patients need more than just gene therapy.
Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the outlook for patients feels shakier.
By Alexandra Pecci • Nov. 1, 2024 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Rare Disease Warriors
Pharma pros driving drug development and access for patients with high unmet needs.
By Meagan Parrish • Oct. 29, 2024 -
Buda Mendes via Getty Images
Dengue is spreading and Sanofi is pulling the U.S. market’s only vaccine. What’s next?
As Sanofi prepares to halt production on its dengue vaccine in 2026, locally acquired infections in the U.S. are raising the alarm.
By Alexandra Pecci • Oct. 23, 2024 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Patient Champions
Leaders advancing health advocacy, DEI initiatives and better medicine access for patients.
By Meagan Parrish • Oct. 22, 2024 -
Permission granted by Parexel
Clinical staff that feel like ‘tech support’ — and other issues a CRO exec contends with
From tech-related challenges to an ongoing staffing crunch, Parexel’s CEO explains what the clinical trials industry is up against.
By Meagan Parrish • Oct. 18, 2024 -
Stock via Getty Images
BMS’ next act for Cobenfy — and other highs and lows in Alzheimer’s
The Alzheimer’s space is booming, from a new use for a schizophrenia drug to discovered pathways linked to the disease — but there’s been stumbles too.
By Meagan Parrish • Oct. 11, 2024 -
Courtesy of Madrigal
How Madrigal plans to win on the market with the first MASH drug
Despite the drug’s wide patient pool, Madrigal is taking a targeted approach with its first launch.
By Amy Baxter • Oct. 10, 2024 -
Stock via Getty Images
Behind the rise of BMS’ Cobenfy, the first new schizophrenia drug in decades
The FDA OK for KarXT, now known as Cobenfy, demonstrates Bristol Myers Squibb’s dealmaking prowess and marks a turning point for a new generation of treatments.
By Kelly Bilodeau • Sept. 26, 2024 -
Stock via Getty Images
Fresh data intensifies race for a major gene therapy target
4D Molecular Therapeutics reported positive interim analysis in the high-potential wet AMD indication last week.
By Meagan Parrish • Sept. 25, 2024 -
Stock via Getty Images
Patient access: How Novartis, Eli Lilly, and other Big Pharmas measure up
A new report examines the patient reach efforts of 20 of the world’s largest pharma companies in low- and middle-income countries.
By Alexandra Pecci • Sept. 23, 2024 -
Stock via Getty Images
The hunt for game-changers against the deadliest form of brain cancer
Treatments for glioblastoma have fallen short in the face of difficult challenges, but the pipeline is full of renewed attempts.
By Kelly Bilodeau • Sept. 16, 2024 -
stock.adobe.com/Syda Productions
Sponsored by LabConnectAgility in action: 5 ways to fast-track your clinical trial
Five ways to beat study timeline pressures and get medicines to patients faster.
Sept. 16, 2024 -
Permission granted by Organon
Why pharma should redefine ‘women’s health’
A broader approach recognizes the challenges disproportionately impacting women and could lead to better outcomes, according to Organon.
By Alexandra Pecci • Sept. 11, 2024 -
George Frey/Reuters
Deep DiveA decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology
Over the past 10 years, PD1-blocking medicines have transformed cancer care. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes.
By Jonathan Gardner • Sept. 10, 2024
